Incruse Ellipta Inhaler

Incruse Ellipta is a prescription medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The active ingredient is umeclidinium, delivered via the Ellipta dry powder inhaler device.

Developed by the British pharmaceutical giant GlaxoSmithKline (GSK), the brand represents a core part of their respiratory health portfolio. The Ellipta device itself was developed as a unified platform for various GSK respiratory medicines to simplify dosing for patients.

Manufacturing primarily takes place in the United Kingdom, specifically at GSK's specialized respiratory production facilities such as the Ware site in Hertfordshire. GSK remains the ultimate owner and global distributor of the Incruse Ellipta brand, maintaining its headquarters in London, United Kingdom.